140 related articles for article (PubMed ID: 36055572)
1. A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.
Wang X; Hong Y; Meng S; Gong W; Ren T; Zhang T; Liu X; Li L; Qiu L; Qian Z; Zhou S; Zhao M; Zhai Q; Meng B; Ren X; Zhang H; Wang X
Clin Immunol; 2022 Oct; 243():109105. PubMed ID: 36055572
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
3. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Hu S; Xu-Monette ZY; Balasubramanyam A; Manyam GC; Visco C; Tzankov A; Liu WM; Miranda RN; Zhang L; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhao X; Winter JN; Zhang M; Li L; Møller MB; Piris MA; Li Y; Go RS; Wu L; Medeiros LJ; Young KH
Blood; 2013 Apr; 121(14):2715-24. PubMed ID: 23343832
[TBL] [Abstract][Full Text] [Related]
4. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Xu-Monette ZY; Wu L; Visco C; Tai YC; Tzankov A; Liu WM; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Kahl BS; Winter JN; Xu W; Li J; Go RS; Li Y; Piris MA; Møller MB; Miranda RN; Abruzzo LV; Medeiros LJ; Young KH
Blood; 2012 Nov; 120(19):3986-96. PubMed ID: 22955915
[TBL] [Abstract][Full Text] [Related]
5. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
6. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
7. An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup.
Chan FC; Telenius A; Healy S; Ben-Neriah S; Mottok A; Lim R; Drake M; Hu S; Ding J; Ha G; Scott DW; Kridel R; Bashashati A; Rogic S; Johnson N; Morin RD; Rimsza LM; Sehn L; Connors JM; Marra MA; Gascoyne RD; Shah SP; Steidl C
Blood; 2015 Feb; 125(6):959-66. PubMed ID: 25395426
[TBL] [Abstract][Full Text] [Related]
8. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
9. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
10. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.
Falduto A; Cimino F; Speciale A; Musolino C; Gangemi S; Saija A; Allegra A
Blood Rev; 2017 Jul; 31(4):235-249. PubMed ID: 28262268
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.
Liu D; Wang Y; Dong M; Guan S; Wang Y; Sun H; Wu N; Li S; Bai J; Chen F; Sun D; Jin Y
Ann Hematol; 2017 Feb; 96(2):227-235. PubMed ID: 27822610
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
Wong KK; Gascoyne DM; Brown PJ; Soilleux EJ; Snell C; Chen H; Lyne L; Lawrie CH; Gascoyne RD; Pedersen LM; Møller MB; Pulford K; Murphy D; Green TM; Banham AH
Leukemia; 2014 Feb; 28(2):362-72. PubMed ID: 23884370
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
[TBL] [Abstract][Full Text] [Related]
15. TP53 and outcome in DLBCL: not only the coding region.
Jardin F; Coiffier B
Blood; 2013 May; 121(22):4433-4. PubMed ID: 23723442
[TBL] [Abstract][Full Text] [Related]
16. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutations and rituximab-CHOP.
Gisselbrecht C
Blood; 2012 Nov; 120(19):3867-9. PubMed ID: 23144158
[No Abstract] [Full Text] [Related]
18. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Johnson NA; Slack GW; Savage KJ; Connors JM; Ben-Neriah S; Rogic S; Scott DW; Tan KL; Steidl C; Sehn LH; Chan WC; Iqbal J; Meyer PN; Lenz G; Wright G; Rimsza LM; Valentino C; Brunhoeber P; Grogan TM; Braziel RM; Cook JR; Tubbs RR; Weisenburger DD; Campo E; Rosenwald A; Ott G; Delabie J; Holcroft C; Jaffe ES; Staudt LM; Gascoyne RD
J Clin Oncol; 2012 Oct; 30(28):3452-9. PubMed ID: 22851565
[TBL] [Abstract][Full Text] [Related]
19. Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Lee HJ; Shin DH; Kim KB; Shin N; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY
Leuk Lymphoma; 2014 Sep; 55(9):2056-63. PubMed ID: 24304372
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic developments and advances in B-cell lymphoma].
Miyazaki K
Rinsho Ketsueki; 2022; 63(6):619-625. PubMed ID: 35831197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
